{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-034390","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2023-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.203921+00:00","generated_at":"2026-06-19T16:15:03.892741+00:00","sec_items":["2.02","2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Frequency Therapeutics cuts 55% of workforce, appoints interim CEO as Lucchino takes medical leave","bullets":["Cash, cash equivalents and marketable securities $83.1M as of Dec 31, 2022 (preliminary); $68.9M net of debt.","Workforce reduction of ~55% approved Feb 11, 2023; completion by April 30, 2023; ~$4M in severance costs.","CEO David Lucchino on temporary medical leave due to bacterial meningitis; co-founder/CSO Christopher Loose named Interim CEO.","Chief Development Officer Carl LeBel stepping down effective March 31, 2023 as part of the reduction.","Company focusing capital on pre-clinical remyelination program for Multiple Sclerosis."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-034390","json":"https://secwatch.observer/filing/0001193125-23-034390.json","markdown":"https://secwatch.observer/filing/0001193125-23-034390.md","text":"https://secwatch.observer/filing/0001193125-23-034390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523034390/0001193125-23-034390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523034390/d463460d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T16:15:03.892741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b5d5cb9f2","claim":"Christopher Loose was appointed as Interim Chief Executive Officer at Korro Bio, Inc..","evidence_excerpt":"On February 11, 2023, the Company’s Board of Directors appointed Christopher Loose, Ph.D., as Interim Chief Executive Officer while David Lucchino, the Company’s President and Chief Executive Officer, is on a temporary medical leave of absence after being hospitalized with bacterial meningitis.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523034390/0001193125-23-034390-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"39c4702e54","claim":"Carl P. LeBel departed as Chief Development Officer at Korro Bio, Inc..","evidence_excerpt":"As part of the Reduction, Carl P. LeBel, Ph.D. will be stepping down as the Company’s Chief Development Officer, effective March 31, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523034390/0001193125-23-034390-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"stepping down"},{"label":"Role","value":"Chief Development Officer"}],"fact_type":"executive_change"},{"claim_id":"81f36ac992a48c5c054b1457d20e003e4029969f","claim":"Korro Bio, Inc. announced a restructuring with charges of approximately $4 million (approximately 55% of its workforce).","evidence_excerpt":"Also on February 13, 2023, the Company announced a reduction in force (the “Reduction”) of approximately 55% of its workforce. The purpose of the Reduction, which was approved by the Board of Directors of the Company on February 11, 2023, is to better align the Company’s workforce with the needs of its business and focus more of its capital resources on its pre-clinical program for remyelination in Multiple Sclerosis (the “MS Program”). These changes will preserve capital, ensuring that the Company is appropriately resourced to complete a first clinical trial of its MS Program. The Reduction will take place in phases and be completed by April 30, 2023. The total costs related to the Reduction are estimated to be approximately $4 million in future cash outlays primarily related to severance costs and related expenses.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523034390/0001193125-23-034390-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $4 million"},{"label":"Headcount","value":"approximately 55% of its workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}